Pete Caruso
@petecaruso.bsky.social
Interested in research and awareness of invisible chronic illnesses: ME, Long COVID, Post Vaccine injury, POTS, Sjogrens, and Lyme.
Pfp: A man wearing a green face mask
Banner: Colorful MEmes from patient-led Long COVID and ME awareness
Pfp: A man wearing a green face mask
Banner: Colorful MEmes from patient-led Long COVID and ME awareness
Rituximab and Ianalumab develop B cell depletion differently: Rituximab is a first line choice for CD20-driven diseases like non-Hodgkin lymphoma or RA, while Ianalumab shows promise in broader B-cell depletion and BAFF-R inhibition, such as SLE or Sjögren’s disease.
August 18, 2025 at 4:19 AM
Rituximab and Ianalumab develop B cell depletion differently: Rituximab is a first line choice for CD20-driven diseases like non-Hodgkin lymphoma or RA, while Ianalumab shows promise in broader B-cell depletion and BAFF-R inhibition, such as SLE or Sjögren’s disease.
Reposted by Pete Caruso
April 1, 2025 at 7:54 PM
NIH RECOVER cuts have started. There’s still time to contact Congress and ask them to stop the Long COVID Recover cuts. See easy toolkit by Long COVID Campaign to send a message.
#NotLongCOVIDcuts
bsky.app/profile/lcca...
#NotLongCOVIDcuts
bsky.app/profile/lcca...
March 28, 2025 at 4:21 PM
NIH RECOVER cuts have started. There’s still time to contact Congress and ask them to stop the Long COVID Recover cuts. See easy toolkit by Long COVID Campaign to send a message.
#NotLongCOVIDcuts
bsky.app/profile/lcca...
#NotLongCOVIDcuts
bsky.app/profile/lcca...